within Pharmacolibrary.Drugs.ATC.R;

model R03BB04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.19,
    Cl             = 14.466666666666667,
    adminDuration  = 600,
    adminMass      = 0.018,
    adminCount     = 1,
    Vd             = 0.032100000000000004,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Tiotropium bromide is a long-acting anticholinergic bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma. It is inhaled and acts by blocking muscarinic receptors in the airways, leading to bronchodilation. Tiotropium is approved and widely used in clinical practice today for maintenance therapy in patients with COPD and for some patients with asthma.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic model in healthy adult volunteers after single 18 mcg inhaled dose using DPI. Parameters based on non-compartmental and compartmental analysis in published clinical trial data.</p><h4>References</h4><ol><li><p>Barnes, PJ (2001). Tiotropium bromide. <i>Expert opinion on investigational drugs</i> 10(4) 733–740. DOI:<a href=&quot;https://doi.org/10.1517/13543784.10.4.733&quot;>10.1517/13543784.10.4.733</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11281822/&quot;>https://pubmed.ncbi.nlm.nih.gov/11281822</a></p></li><li><p>Keating, GM (2012). Tiotropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary disease. <i>Drugs</i> 72(2) 273–300. DOI:<a href=&quot;https://doi.org/10.2165/11208620-000000000-00000&quot;>10.2165/11208620-000000000-00000</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22217233/&quot;>https://pubmed.ncbi.nlm.nih.gov/22217233</a></p></li><li><p>Bouhajib, M, &amp; Tayab, Z (2019). An evaluation of the pharmacokinetics of tiotropium following a single-dose inhalation in healthy subjects using an ultra-sensitive bioanalytical method. <i>Drug development and industrial pharmacy</i> 45(12) 1915–1920. DOI:<a href=&quot;https://doi.org/10.1080/03639045.2019.1680993&quot;>10.1080/03639045.2019.1680993</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31613148/&quot;>https://pubmed.ncbi.nlm.nih.gov/31613148</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end R03BB04;
